BENERVA 20CPR 300MG

BENERVA

active ingredients

Benefit 300 mg gastro-resistant tablets. One tablet contains: thiamin hydrochloride (vitamin B₁300 mg. Benerva 100 mg/1 ml injectable solution for intramuscular use. A 1 ml vial contains: tiamina hydrochloride (vitamin B₁100 mg. For the full list of excipients, see 6.1.

Excellent

Benefit 300 mg gastro-resistant tablets: Talco, povidone K90, magnesium stearate, metacrilic acid - acrylate copolymer (1:1), macrogol 6000, carmellosa sodica. Benerva 100 mg/1 ml injectable solution for intramuscular use: Fenol, glycerol, sodium phosphate monobasic dihydrate, sodium bicarbonate, water for injectable preparations.

Therapeutic indications

Prophylaxis and therapy of vitamin B deficiency₁ from increased demand or reduced absorption (beri-beri and its different clinical forms). Curtain Polyethylene (ethylene). Ethylists' Miocardiopathy. At high doses, coadjuvant therapy of non-facial nevriti and polinevriti.

Contraindications

Tables Hypersensitivity known to the active ingredient or any of the excipients. Fairytale Known or suspect hypersensitivity to the active ingredient or any of the excipients.

Population

Oral administration. Mild and medium gravity cases: 100 mg every 24 hours. Serious cases: 600-1200 mg (2-4 tablets of 300 mg Benerva) per day for 1-2 weeks, then 300 mg (1 tablet of 300 mg Benerva) per day for several weeks. The high-dose Benerva tablets (300 mg) allow for intensive treatment. Parental administration. Parental administration is reserved for cases with altered intestinal absorption, as well as in the initial treatment of acute deficiencies, accompanied by polinevritis, psichic and heart disorders, especially in chronic alcoholism: 50-200 mg i.m. a day.

Conservation

Tables Store in the original packaging. Fairytale Store at a temperature below 25°C, in the original packaging, sheltered from light.

Warnings

Preparations based on vitamin B₁ or derivatives, especially by parenteral means, may cause disturbances in subjects that have had phenomena of sensitization or morbid manifestations from allergopathies. The risk of hypersensitivity reactions is increased with repeated intramuscular administration. Oral administration is therefore preferable where possible.

Interactions

The tiosemicarbazone and 5-fluorouracile inhibit the activity of thiamin. Interferences with laboratory tests: • vitamin B₁ can give false positives in the determination of neurobilinogen with Ehrlich reagent; • high doses of vitamin B₁ can interfere with the spectrophotometric determination of serum theophylline.

Effects

The undesirable effects below result from spontaneous signalling and it is therefore not possible to classify them by frequency categories. Tables. Immune system disorders: In individual cases allergic and anaphylactic reactions were reported, with symptoms such as itching, hives, angioedema, abdominal pain, difficulty breathing, tachycardia, palpitations and shock. Gastrointestinal diseases: Mild gastrointestinal disorders such as nausea, vomiting, diarrhea and abdominal pain have been reported. Fairytale. Systemic pathologies and conditions for administration: Pain in the injection site. Immune system disorders: They were reported, usually after intravenous injection, intramuscular or subcutaneous, allergic and anaphylactic reactions with symptoms such as itching, hives, angioedema, abdominal pain, respiratory difficulties, tachycardia, palpitations and shock. These reactions are often preceded by sneezing or transient itching.

Overdosing

Tables No overdose cases have been reported. Fairytale Insulated clinical cases of toxic reactions to prolonged administration by tyamine parental means are probably hypersensitivity reactions.

This product is not suitable for use during pregnancy or nursing.

Source: Farmadati